Preclinical characterization of PC786, an inhaled small-molecule respiratory syncytial virus L protein polymerase inhibitor

Antimicrobial Agents and Chemotherapy

Volumn 61, Issue 9, 2017, Pages

  Coates, Matthew ^a   Brookes, Daniel ^a   Kim, Young In ^b,c   Allen, Heather ^a   Fordyce, Euan A F ^d   Meals, Elizabeth A ^b,c   Colley, Thomas ^a   Ciana, Claire Lise ^d   Parra, Guillaume F ^d   Sherbukhin, Vladimir ^d   Stockwell, Jennifer A ^d   Thomas, Jennifer C ^d   Hunt, S Fraser ^d   Anderson Dring, Lauren ^a   Onions, Stuart T ^d   Cass, Lindsey ^a   Murray, Peter J ^a   Ito, Kazuhiro ^a   Strong, Pete ^a   DeVincenzo, John P ^b,c   Rapeport, Garth ^a   more..

^a PULMOCIDE LTD   (United Kingdom)

^b UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^c LE BONHEUR CHILDREN S HOSPITAL   (United States)

^d Sygnature Discovery Limited   (United Kingdom)

Author keywords

Bronchial epithelial cell; Clinical isolate; Inhalation; L protein; PC786; Polymerase; Respiratory syncytial virus; RNA polymerases

Indexed keywords

ANTIVIRUS AGENT; RNA DIRECTED RNA POLYMERASE; VIRAL PROTEIN;

ANIMAL; ANTAGONISTS AND INHIBITORS; BIOSYNTHESIS; CELL LINE; DRUG EFFECT; EPITHELIUM CELL; HUMAN; HUMAN RESPIRATORY SYNCYTIAL VIRUS; MOUSE; RAT; RESPIRATORY MUCOSA; RESPIRATORY SYNCYTIAL VIRUS INFECTION; RESPIRATORY TRACT INFECTION; VIROLOGY; VIRUS LOAD; VIRUS REPLICATION;

ANIMALS; ANTIVIRAL AGENTS; CELL LINE; EPITHELIAL CELLS; HUMANS; MICE; RATS; RESPIRATORY MUCOSA; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; RESPIRATORY SYNCYTIAL VIRUS, HUMAN; RESPIRATORY TRACT INFECTIONS; RNA REPLICASE; VIRAL LOAD; VIRAL PROTEINS; VIRUS REPLICATION;

EID: 85028313141     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00737-17     Document Type: Article

References (49)

1. Nair H, Nokes DJ, Gessner BD, Dherani M, Madhi SA, Singleton RJ, O�Brien KL, Roca A, Wright PF, Bruce N, Chandran A, Theodoratou E, Sutanto A, Sedyaningsih ER, Ngama M, Munywoki PK, Kartasasmita C, Simoes EA, Rudan I, Weber MW, Campbell H. 2010. Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: a systematic review and meta-analysis. Lancet 375:1545�1555. https://doi.org/10.1016/S0140-6736(10)60206-1.
2. Walsh EE, Falsey AR. 2012. Respiratory syncytial virus infection in adult populations. Infect Disord Drug Targets 12:98�102. https://doi.org/10.2174/187152612800100116.
3. Mehta J, Walsh EE, Mahadevia PJ, Falsey AR. 2013. Risk factors for respiratory syncytial virus illness among patients with chronic obstructive pulmonary disease. COPD 10:293�299. https://doi.org/10.3109/15412555.2012.744741.
4. Darveaux JI, Lemanske RF, Jr. 2014. Infection-related asthma. J Allergy Clin Immunol Pract 2:658�663. https://doi.org/10.1016/j.jaip.2014.09 .011.
5. Abman SH, Ogle JW, Butler-Simon N, Rumack CM, Accurso FJ. 1988. Role of respiratory syncytial virus in early hospitalizations for respiratory distress of young infants with cystic fibrosis. J Pediatr 113:826�830. https://doi.org/10.1016/S0022-3476(88)80008-8.
6. Abdallah A, Rowland KE, Schepetiuk SK, To LB, Bardy P. 2003. An outbreak of respiratory syncytial virus infection in a bone marrow transplant unit: effect on engraftment and outcome of pneumonia without specific antiviral treatment. Bone Marrow Transplant 32:195�203. https://doi.org/10.1038/sj.bmt.1704116.
7. Leader S, Kohlhase K. 2002. Respiratory syncytial virus-coded pediatric hospitalizations, 1997 to 1999. Pediatr Infect Dis J 21:629�632. https://doi.org/10.1097/00006454-200207000-00005.
8. Thompson WW, Shay DK, Weintraub E, Brammer L, Cox N, Anderson LJ, Fukuda K. 2003. Mortality associated with influenza and respiratory syncytial virus in the United States. JAMA 289:179�186. https:// doi.org/10.1001/jama.289.2.179.
9. Melero JA, Moore ML. 2013. Influence of respiratory syncytial virus strain differences on pathogenesis and immunity. Curr Top Microbiol Immunol 372:59�82.
10. Panayiotou C, Richter J, Koliou M, Kalogirou N, Georgiou E, Christodou-lou C. 2014. Epidemiology of respiratory syncytial virus in children in Cyprus during three consecutive winter seasons (2010�2013): age distribution, seasonality and association between prevalent genotypes and disease severity. Epidemiol Infect 142:2406�2411. https://doi.org/10.1017/S0950268814000028.
11. Ren L, Xiao Q, Zhou L, Xia Q, Liu E. 2015. Molecular characterization of human respiratory syncytial virus subtype B: a novel genotype of subtype B circulating in China. J Med Virol 87:1�9. https://doi.org/10.1002/jmv.23960.
12. Auksornkitti V, Kamprasert N, Thongkomplew S, Suwannakarn K, Theam-boonlers A, Samransamruajkij R, Poovorawan Y. 2014. Molecular characterization of human respiratory syncytial virus, 2010-2011: identification of genotype ON1 and a new subgroup B genotype in Thailand. Arch Virol 159:499 �507. https://doi.org/10.1007/s00705-013-1773-9.
13. Zhu Q, McAuliffe JM, Patel NK, Palmer-Hill FJ, Yang CF, Liang B, Su L, Zhu W, Wachter L, Wilson S, MacGill RS, Krishnan S, McCarthy MP, Losonsky GA, Suzich JA. 2011. Analysis of respiratory syncytial virus preclinical and clinical variants resistant to neutralization by monoclonal antibodies palivizumab and/or motavizumab. J Infect Dis 203:674�682. https://doi.org/10.1093/infdis/jiq100.
14. DeVincenzo JP, Whitley RJ, Mackman RL, Scaglioni-Weinlich C, Harrison L, Farrell E, McBride S, Lambkin-Williams R, Jordan R, Xin Y, Ramanathan S, O'Riordan T, Lewis SA, Li X, Toback SL, Lin SL, Chien JW. 2014. Oral GS-5806 activity in a respiratory syncytial virus challenge study. N Engl J Med 371:711�722. https://doi.org/10.1056/NEJMoa1401184.
15. Blair W, Cox C. 2016. Current landscape of antiviral drug discovery. F1000Res 5(F1000 Faculty Rev):202. https://f1000research.com/articles/5-202/v1.
16. ClinicalTrials.gov. 2016. Safety, efficacy and pharmacokinetics of BTA-C585 in a RSV viral challenge study (NCT02718937). https://clinicaltrials.gov/ct2/show/NCT02718937.
17. Israel S, Rusch S, DeVincenzo J, Boyers A, Fok-Seang J, Huntjens D, Lounis N, Marien K, Stevens M, Verloes R. 2016. Effect of oral JNJ-53718678 (JNJ-678) on disease severity in healthy adult volunteers experimentally inoculated with live respiratory syncytial virus (RSV): a placebo-controlled challenge study. Open Forum Infect Dis 3:650. https://doi.org/10.1093/ofid/ofw172.513.
18. ClinicalTrials.gov. 2016. Study to evaluate antiviral activity, safety, and pharmacokinetics of repeated doses of orally administered JNJ 53718678 against respiratory syncytial virus infection (NCT02387606). https://www.clinicaltrials.gov/ct2/show/NCT02387606.
19. Detalle L, Stohr T, Palomo C, Piedra PA, Gilbert BE, Mas V, Millar A, Power UF, Stortelers C, Allosery K, Melero JA, Depla E. 2016. Generation and characterization of ALX-0171, a potent novel therapeutic nanobody for the treatment of respiratory syncytial virus infection. Antimicrob Agents Chemother 60:6�13. https://doi.org/10.1128/AAC.01802-15.
20. DeVincenzo JP, McClure MW, Symons JA, Fathi H, Westland C, Chanda S, Lambkin-Williams R, Smith P, Zhang Q, Beigelman L, Blatt LM, Fry J. 2015. Activity of oral ALS-008176 in a respiratory syncytial virus challenge study. N Engl J Med 373:2048�2058. https://doi.org/10.1056/NEJMoa1413275.
21. Hall CB, Douglas RG, Jr, Schnabel KC, Geiman JM. 1981. Infectivity of respiratory syncytial virus by various routes of inoculation. Infect Immun 33:779�783.
22. Welliver TP, Garofalo RP, Hosakote Y, Hintz KH, Avendano L, Sanchez K, Velozo L, Jafri H, Chavez-Bueno S, Ogra PL, McKinney L, Reed JL, Welliver RC, Sr. 2007. Severe human lower respiratory tract illness caused by respiratory syncytial virus and influenza virus is characterized by the absence of pulmonary cytotoxic lymphocyte responses. J Infect Dis 195:1126�1136. https://doi.org/10.1086/512615.
23. Johnson JE, Gonzales RA, Olson SJ, Wright PF, Graham BS. 2007. The histopathology of fatal untreated human respiratory syncytial virus infection. Mod Pathol 20:108�119. https://doi.org/10.1038/modpathol.3800725.
24. Sudo K, Miyazaki Y, Kojima N, Kobayashi M, Suzuki H, Shintani M, Shimizu Y. 2005. YM-53403, a unique anti-respiratory syncytial virus agent with a novel mechanism of action. Antiviral Res 65:125�131. https://doi.org/10.1016/j.antiviral.2004.12.002.
25. Noton SL, Nagendra K, Dunn EF, Mawhorter ME, Yu Q, Fearns R. 2015. Respiratory syncytial virus inhibitor AZ-27 differentially inhibits different polymerase activities at the promoter. J Virol 89:7786�7798. https://doi .org/10.1128/JVI.00530-15.
26. Xiong H, Foulk M, Aschenbrenner L, Fan J, Tiong-Yip CL, Johnson KD, Moustakas D, Fleming PR, Brown DG, Zhang M, Ferguson D, Wu D, Yu Q. 2013. Discovery of a potent respiratory syncytial virus RNA polymerase inhibitor. Bioorg Med Chem Lett 23:6789 � 6793. https://doi.org/10.1016/j.bmcl.2013.10.018.
27. Liuzzi M, Mason SW, Cartier M, Lawetz C, McCollum RS, Dansereau N, Bolger G, Lapeyre N, Gaudette Y, Lagace L, Massariol MJ, Do F, Whitehead P, Lamarre L, Scouten E, Bordeleau J, Landry S, Rancourt J, Fazal G, Simoneau B. 2005. Inhibitors of respiratory syncytial virus replication target cotranscriptional mRNA guanylylation by viral RNA-dependent RNA polymerase. J Virol 79:13105�13115. https://doi.org/10.1128/JVI.79.20.13105-13115.2005.
28. Hunt SM, Onions ST, Sherbukhin V, Fordyce EAF, Murray PJ, Brookes DW, Ito K, Strong P. 14 April 2016. Novel 5,6-dihydro-4H-benzo[b]thieno-[2,3-d]azepine derivative. Patent WO/2016/055791A1.
29. Tiong-Yip CL, Aschenbrenner L, Johnson KD, McLaughlin RE, Fan J, Challa S, Xiong H, Yu Q. 2014. Characterization of a respiratory syncytial virus L protein inhibitor. Antimicrob Agents Chemother 58:3867�3873. https://doi.org/10.1128/AAC.02540-14.
30. Bem RA, Domachowske JB, Rosenberg HF. 2011. Animal models of human respiratory syncytial virus disease. Am J Physiol Lung Cell Mol Physiol 301:L148�156. https://doi.org/10.1152/ajplung.00065.2011.
31. DeVincenzo JP, Wilkinson T, Vaishnaw A, Cehelsky J, Meyers R, Nochur S, Harrison L, Meeking P, Mann A, Moane E, Oxford J, Pareek R, Moore R, Walsh E, Studholme R, Dorsett P, Alvarez R, Lambkin-Williams R. 2010. Viral load drives disease in humans experimentally infected with respiratory syncytial virus. Am J Respir Crit Care Med 182:1305�1314. https://doi.org/10.1164/rccm.201002-0221OC.
32. Thompson TM, Roddam PL, Harrison LM, Aitken JA, DeVincenzo JP. 2015. Viral specific factors contribute to clinical respiratory syncytial virus disease severity differences in infants. Clin Microbiol 4(3):206. https://doi.org/10.4172/2327-5073.1000206.
33. Wu H, Pfarr DS, Johnson S, Brewah YA, Woods RM, Patel NK, White WI, Young JF, Kiener PA. 2007. Development of motavizumab, an ultra-potent antibody for the prevention of respiratory syncytial virus infection in the upper and lower respiratory tract. J Mol Biol 368:652�665. https://doi.org/10.1016/j.jmb.2007.02.024.
34. Zhang L, Peeples ME, Boucher RC, Collins PL, Pickles RJ. 2002. Respiratory syncytial virus infection of human airway epithelial cells is polarized, specific to ciliated cells, and without obvious cytopathology. J Virol 76: 5654�5666. https://doi.org/10.1128/JVI.76.11.5654-5666.2002.
35. Villenave R, Shields MD, Power UF. 2013. Respiratory syncytial virus interaction with human airway epithelium. Trends Microbiol 21:238�244. https://doi.org/10.1016/j.tim.2013.02.004.
36. Chapman J, Abbott E, Alber DG, Baxter RC, Bithell SK, Henderson EA, Carter MC, Chambers P, Chubb A, Cockerill GS, Collins PL, Dowdell VC, Keegan SJ, Kelsey RD, Lockyer MJ, Luongo C, Najarro P, Pickles RJ, Simmonds M, Taylor D, Tyms S, Wilson LJ, Powell KL. 2007. RSV604, a novel inhibitor of respiratory syncytial virus replication. Antimicrob Agents Chemother 51: 3346�3353. https://doi.org/10.1128/AAC.00211-07.
37. Deval J, Hong J, Wang G, Taylor J, Smith LK, Fung A, Stevens SK, Liu H, Jin Z, Dyatkina N, Prhavc M, Stoycheva AD, Serebryany V, Liu J, Smith DB, Tam Y, Zhang Q, Moore ML, Fearns R, Chanda SM, Blatt LM, Symons JA, Beigelman L. 2015. Molecular basis for the selective inhibition of respiratory syncytial virus RNA polymerase by 2=-fluoro-4=-chloromethyl-cytidine triphosphate. PLoS Pathog 11:e1004995. https://doi.org/10.1371/journal.ppat.1004995.
38. Perron M, Stray K, Kinkade A, Theodore D, Lee G, Eisenberg E, Sangi M, Gilbert BE, Jordan R, Piedra PA, Toms GL, Mackman R, Cihlar T. 2015. GS-5806 inhibits a broad range of respiratory syncytial virus clinical isolates by blocking the virus-cell fusion process. Antimicrob Agents Chemother 60:1264�1273. https://doi.org/10.1128/AAC.01497-15.
39. Deval J, Fung A, Stevens SK, Jordan PC, Gromova T, Taylor JS, Hong J, Meng J, Wang G, Dyatkina N, Prhavc M, Symons JA, Beigelman L. 2016. Biochemical effect of resistance mutations against synergistic inhibitors of RSV RNA polymerase. PLoS One 11:e0154097. https://doi.org/10.1371/journal.pone.0154097.
40. Eltahla AA, Luciani F, White PA, Lloyd AR, Bull RA. 2015. Inhibitors of the hepatitis C virus polymerase; mode of action and resistance. Viruses 7:5206�5224. https://doi.org/10.3390/v7102868.
41. Christen MT, Menon L, Myshakina NS, Ahn J, Parniak MA, Ishima R. 2012. Structural basis of the allosteric inhibitor interaction on the HIV-1 reverse transcriptase RNase H domain. Chem Biol Drug Des 80:706 �716. https:// doi.org/10.1111/cbdd.12010.
42. Ghildyal R, Ho A, Jans DA. 2006. Central role of the respiratory syncytial virus matrix protein in infection. FEMS Microbiol Rev 30:692�705. https://doi.org/10.1111/j.1574-6976.2006.00025.x.
43. Do LA, Wilm A, Van Doorn HR, Lam HM, Sim S, Sukumaran R, Tran AT, Nguyen BH, Tran TT, Tran QH, Vo QB, Dac NA, Trinh HN, Nguyen TT, Binh BT, Le K, Nguyen MT, Thai QT, Vo TV, Ngo NQ, Dang TK, Cao NH, Tran TV, Ho LV, Farrar J, Jong M, Chen S, Nagarajan N, Bryant JE, Hibberd ML. 2015. Direct whole-genome deep-sequencing of human respiratory syncytial virus A and B from Vietnamese children identifies distinct patterns of inter- and intra-host evolution. J Gen Virol 96:3470�3483. https://doi.org/10.1099/jgv.0.000298.
44. Grad YH, Newman R, Zody M, Yang X, Murphy R, Qu J, Malboeuf CM, Levin JZ, Lipsitch M, DeVincenzo J. 2014. Within-host whole-genome deep sequencing and diversity analysis of human respiratory syncytial virus infection reveals dynamics of genomic diversity in the absence and presence of immune pressure. J Virol 88:7286�7293. https://doi.org/10.1128/JVI.00038-14.
45. Mackman RL, Sangi M, Sperandio D, Parrish JP, Eisenberg E, Perron M, Hui H, Zhang L, Siegel D, Yang H, Saunders O, Boojamra C, Lee G, Samuel D, Babaoglu K, Carey A, Gilbert BE, Piedra PA, Strickley R, Iwata Q, Hayes J, Stray K, Kinkade A, Theodore D, Jordan R, Desai M, Cihlar T. 2015. Discovery of an oral respiratory syncytial virus (RSV) fusion inhibitor (GS-5806) and clinical proof of concept in a human RSV challenge study. J Med Chem 58:1630�1643. https://doi.org/10.1021/jm5017768.
46. Wang G, Deval J, Hong J, Dyatkina N, Prhavc M, Taylor J, Fung A, Jin Z, Stevens SK, Serebryany V, Liu J, Zhang Q, Tam Y, Chanda SM, Smith DB, Symons JA, Blatt LM, Beigelman L. 2015. Discovery of 4=-chloromethyl-2=-deoxy-3=,5=-di-O-isobutyryl-2=-fluorocytidine (ALS-8176), a first-in-class RSV polymerase inhibitor for treatment of human respiratory syncytial virus infection. J Med Chem 58:1862�1878. https://doi.org/10.1021/jm5017279.
47. Dochow M, Krumm SA, Crowe JE, Jr, Moore ML, Plemper RK. 2012. Independent structural domains in paramyxovirus polymerase protein. J Biol Chem 287:6878�6891. https://doi.org/10.1074/jbc.M111.325258.
48. Perkins SM, Webb DL, Torrance SA, El Saleeby C, Harrison LM, Aitken JA, Patel A, DeVincenzo JP. 2005. Comparison of a real-time reverse transcriptase PCR assay and a culture technique for quantitative assessment of viral load in children naturally infected with respiratory syncytial virus. J Clin Microbiol 43:2356�2362. https://doi.org/10.1128/JCM.43.5.2356-2362.2005.
49. Mason SW, Lawetz C, Gaudette Y, Do F, Scouten E, Lagace L, Simoneau B, Liuzzi M. 2004. Polyadenylation-dependent screening assay for respiratory syncytial virus RNA transcriptase activity and identification of an inhibitor. Nucleic Acids Res 32:4758�4767. https://doi.org/10.1093/nar/gkh809.